Neurocrine biosciences, inc. (NBIX)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash Flows from Operating Activities:
Net loss

37,400

34,000

53,789

51,323

-102,100

18,078

50,764

-5,913

-41,818

6,894

-11,125

-59,985

-78,326

-44,659

-36,887

-40,280

-19,264

-29,315

-34,435

-23,987

-1,192

-19,444

-15,875

-13,381

-11,842

-10,642

-11,131

-12,242

-12,075

9,490

-3,078

-501

-886

1,331

31,382

1,976

2,882

Reconciliation of net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation expense

22,800

21,317

20,250

17,895

15,800

13,268

13,070

11,851

19,879

13,452

10,204

9,890

8,976

7,953

6,319

7,274

6,918

6,226

13,903

4,663

3,600

2,444

2,664

2,827

2,447

1,696

1,711

1,680

1,732

1,310

1,370

1,373

1,426

907

904

395

712

Depreciation

2,100

-

-

-

1,600

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

1,080

883

786

-

616

589

489

445

408

324

276

270

244

251

244

224

217

208

178

156

168

172

175

176

163

166

152

142

138

174

240

Amortization of debt discount

5,000

4,865

4,774

4,683

4,600

4,512

4,428

4,347

4,265

4,182

4,104

2,651

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

300

353

349

387

300

337

334

329

326

322

319

207

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (accretion of discounts) amortization of premiums on investments

-

-

-

-

-

-13

-372

-552

-512

-554

-606

-327

-269

-369

-711

-1,043

-1,397

-1,721

-1,732

-1,568

-1,011

-1,047

-1,151

-977

-617

-735

-750

-719

-639

-655

-990

-867

-623

-569

-619

-652

-501

Change in fair value of equity security investments

-16,500

-

-

-

1,700

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of restricted equity securities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

10,231

0

0

0

0

-730

-729

-730

-730

-7,986

-7,990

-9,029

-9,237

-9,239

-9,238

-9,244

-9,306

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-125

-114

-86

-72

-72

-64

-41

-28

80

-27

-5

7

6

6

27

39

38

38

67

79

79

80

102

117

116

99

Gain on sales of assets, net

-

-

-

-

-

-

-

-

-

-

-

881

879

863

844

868

856

838

828

829

839

812

806

810

794

788

787

800

795

773

759

759

783

802

822

755

816

Cease-use expense

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-584

-85

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-7

-87

76

100

Other

400

-38

676

316

-200

73

-62

-191

-229

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

22,100

11,257

18,795

23,417

15,700

1,677

11,917

-1,978

13,497

1,309

23,744

5,295

779

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

3,900

6,490

-1,220

-646

1,800

-383

636

2,962

309

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current assets

-

-

-

-

-

-

-180

2,453

441

-

1,878

2,437

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued liabilities

-16,200

41,611

4,605

24,339

-16,600

8,646

11,304

12,143

-7,870

16,231

10,480

7,554

-6,927

3,520

-306

3,531

-2,347

5,884

2,284

2,219

-546

1,547

1,922

1,356

-1,127

-923

-554

1,496

-968

-541

1,189

794

-1,999

1,234

82

1,852

-3,019

Other current assets and liabilities, net

4,100

-

-

-

-3,300

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cease-use liability

-

-

-

-

-

-

-

-

-

-

-

-

-66

-

-58

-71

-110

-83

-175

-239

-113

-110

-104

-102

-102

-102

-97

-197

-194

-70

-64

-65

-64

-4,340

-729

-1,219

-1,214

Accounts receivable under collaboration agreements and other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14,577

-

-

-

30,552

-

-

-

-850

416

150

-4

-14,090

12,194

339

-170

515

-21,122

19,617

-67

-1,241

Other liabilities

-

-

-

-

-

-

0

-85

-90

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1

27

-1

-

-

-

-

Net cash provided by (used in) operating activities

38,200

102,553

97,826

64,175

-112,500

50,454

68,917

20,479

-38,486

40,575

-9,310

-48,239

-77,357

-31,625

-31,010

-14,335

-29,211

-15,203

-18,572

13,961

-18,183

-15,309

-12,099

-9,965

-9,767

-10,879

-10,780

-9,860

1,912

-8,909

-8,303

-6,878

-11,204

11,020

2,772

-5,910

-8,580

Cash Flows from Investing Activities:
Purchases of marketable securities

-

-

-

-

-

-

-

-

139,354

138,870

79,506

307,155

57,877

81,635

47,653

113,927

55,561

72,615

89,577

127,639

159,221

16,388

32,819

99,430

108,907

14,949

34,767

29,111

66,501

26,808

16,344

47,776

75,385

34,913

28,307

25,230

50,649

Sales and maturities of marketable securities

-

-

-

-

-

-

-

-

84,086

81,853

46,911

94,239

116,085

97,050

91,626

100,396

126,754

95,495

42,009

74,221

43,398

32,760

36,304

41,678

43,391

35,975

33,487

50,349

31,470

54,731

27,334

19,907

30,548

32,622

46,668

25,533

29,453

Purchases of debt securities available-for-sale

172,000

-

231,189

119,601

116,300

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and maturities of debt securities available-for-sale

206,500

-

149,083

123,840

215,900

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of equity securities

-

14,135

0

20

54,700

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investment in equity securities

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

1,300

2,812

3,544

4,492

3,900

6,010

12,359

4,643

1,800

2,377

2,804

397

1,362

347

777

2,243

741

828

316

510

280

439

269

649

255

191

31

264

59

42

335

190

404

40

562

128

20

Deposits and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-108

200

0

-24

-16

0

-

-

-

-

-

-

-

-

-

-

-

-

-1,822

24

0

2

Proceeds from sales of property and equipment

-

-

-

-

-

4

0

12

18

0

7

0

0

0

0

10

3

0

0

0

9

0

0

5

40

2

38

-13

13

7

53

-53

25

58

86

18

83

Net cash provided by investing activities

33,200

-166,158

-85,646

-269

41,000

-106,256

-45,095

-34,514

-57,050

-59,394

-35,392

-213,313

56,846

15,160

43,196

-15,656

70,255

22,052

-47,860

-53,912

-116,094

15,545

3,216

-58,396

-65,731

20,729

-1,305

20,993

-35,077

27,887

10,655

-28,087

-45,216

-451

17,861

193

-21,135

Cash Flows from Financing Activities:
Issuance of common stock

3,300

7,284

13,164

4,265

2,600

1,782

5,490

6,123

16,135

5,600

3,022

3,712

1,531

63

1,329

936

62

968

740

1,759

273,525

1,732

484

274

136,241

50

2,661

1,625

966

288

118

43

83,253

22

45

162

57

Net cash provided by financing activities

3,300

7,284

13,164

4,265

2,600

1,782

5,490

6,123

16,135

5,600

3,022

506,493

1,531

63

1,329

936

62

968

740

1,759

273,525

1,732

484

274

136,241

50

2,661

1,625

966

288

118

43

83,253

22

45

162

57

Change in cash and cash equivalents and restricted cash

74,700

-56,321

25,344

68,171

-68,900

-54,020

29,312

-7,912

-79,401

-13,219

-41,680

244,941

-18,980

-16,402

13,515

-29,055

41,106

7,817

-65,692

-38,192

139,248

1,968

-8,399

-68,087

60,743

9,900

-9,424

12,758

-32,199

19,266

2,470

-34,922

26,833

10,591

20,678

-5,555

-29,658

Supplemental Disclosure:
Non-cash capital expenditures

800

898

-856

311

600

516

-1,436

3,238

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-